Literature DB >> 12709875

Challenges for clinical trials to treat progressive multifocal leukoencephalopathy.

David B Clifford1.   

Abstract

Progressive multifocal leukoencephalopathy is a lethal complication of immunodeficiency for which no direct therapy has been achieved. The issues that have made this disease especially difficult to address are discussed, and an outline for development of future interventions is provided. A controlled trial of therapy utilizing an international group of trial groups is proposed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12709875     DOI： 10.1080/13550280390195324

Source DB:  PubMed          Journal:  J Neurovirol        ISSN： 1355-0284            Impact factor:   2.643


  17 in total

1.  Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV.

Authors:  J M Tassie; J Gasnault; M Bentata; J Deloumeaux; F Boué; E Billaud; D Costagliola
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

2.  HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy.

Authors:  D B Clifford; C Yiannoutsos; M Glicksman; D M Simpson; E J Singer; P J Piliero; C M Marra; G S Francis; J C McArthur; K L Tyler; A C Tselis; N E Hyslop
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

3.  Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy.

Authors:  P Cinque; S Casari; D Bertelli
Journal:  N Engl J Med       Date:  1998-09-17       Impact factor: 91.245

4.  Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response.

Authors:  B Giudici; B Vaz; S Bossolasco; S Casari; A M Brambilla; W Lüke; A Lazzarin; T Weber; P Cinque
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

5.  JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis.

Authors:  M T Pho; A Ashok; W J Atwood
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 6.  Convection-enhanced intraparenchymal delivery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoencephalopathy (PML).

Authors:  R M Levy; E Major; M J Ali; B Cohen; D Groothius
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

7.  A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy.

Authors:  W J Atwood
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

8.  Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy.

Authors:  R R Razonable; A J Aksamit; A J Wright; J W Wilson
Journal:  Mayo Clin Proc       Date:  2001-11       Impact factor: 7.616

9.  The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line.

Authors:  J Hou; E O Major
Journal:  J Neurovirol       Date:  1998-08       Impact factor: 2.643

10.  A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS.

Authors:  Christina M Marra; Natasa Rajicic; David E Barker; Bruce A Cohen; David Clifford; M Judith Donovan Post; Armando Ruiz; Brian C Bowen; Meei-Li Huang; Jennie Queen-Baker; Janet Andersen; Sue Kelly; Sharon Shriver
Journal:  AIDS       Date:  2002-09-06       Impact factor: 4.177
View more
  1 in total

1.  Interferon- alpha and - beta restrict polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy.

Authors:  Juliene K G Co; Saguna Verma; Ulziijargal Gurjav; Laarni Sumibcay; Vivek R Nerurkar
Journal:  J Infect Dis       Date:  2007-07-20       Impact factor: 5.226
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.